Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 17, 2023
Daily News
November 17, 2023
- Novo Nordisk to Quit Ozempic’s Single-Dose Devices, Focus on Multi-Dose Pen
November 17, 2023
- Astellas to Acquire US Upstart Propella for Prostate Cancer Drug
November 17, 2023
- Japan Agrees to Buy 1.4 Million Doses of Daiichi Sankyo’s COVID Vaccine
November 17, 2023
- Japanese Pricing Rules Don’t Fully Capture Value of New Modalities, “No” to CEA Expansion: Janssen Exec
November 17, 2023
- LDP Raises Stable Drug Supply as Major Topic of FY2024 Budget Formulation
November 17, 2023
- Meiji’s mRNA Vaccine, Daiichi’s XBB.1.5 Jab Up for Nov. 27 PAFSC Session
November 17, 2023
- Israel-Palestine Conflict to Have Limited Impact on Japan Pharma Sector for Now: JPMA
November 17, 2023
- JPMA Gearing Up for Drug Pricing Reform Debate towards December: Exec
November 17, 2023
- Novo Nordisk Curbs Insulin Shipments Due to Surge in Demand for Diabetes Meds
November 17, 2023
- Astellas, University of Tsukuba Tie Up in Drug Discovery and Startup Incubation
November 17, 2023
- Xocova, Dayvigo Again Winner in Sept Rep Promotion Rankings for GPs, HPs: Intage
November 17, 2023
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…